---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001572"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:11:34.346507+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q4 2022 net revenue $128.3M (+41% YoY); full-year net income $181.5M

## Summary
- Q4 net product revenue $128.3M, up 41% YoY; average patients on WAKIX ~4,900.
- GAAP net income Q4 $48.5M ($0.79 diluted EPS); non-GAAP adjusted $61.9M ($1.01).
- Full year 2022 net revenue $437.9M (+43% YoY); net income $181.5M.
- Phase 3 idiopathic hypersomnia INTUNE study continues with strong momentum.

## SEC filing metadata
- accession: 0001558370-23-001572
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/0001558370-23-001572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/hrmy-20230221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001572
- JSON: https://secwatch.observer/filing/0001558370-23-001572.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001572.txt

## Key facts
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 21, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/0001558370-23-001572-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.